It was previously reported that NRP1 negatively controls the expression of p27/Kip1 cyclin-dependent kinase inhibitor in cancer cells, a mechanism required to unleash the pathway leading to EGFR upregulation in PLX-resistant melanoma cells [7,21]. This evidence concerns the gene CDKN1B and cancer.